Cardiotoxicity remains a dreaded complication for patients undergoing herceptin and doxorubicin treatment. Though many studies looked at racial disparities in heart failure patients, minimal data are present for the cardio-oncology… Click to show full abstract
Cardiotoxicity remains a dreaded complication for patients undergoing herceptin and doxorubicin treatment. Though many studies looked at racial disparities in heart failure patients, minimal data are present for the cardio-oncology population. We queried the echocardiogram database at a safety net
               
Click one of the above tabs to view related content.